(i) State of the art Parkinson’s disease (PD) is a neurodegenerative disorders characterised by progressive loss of dopamine innervation in the striatum. While Levodopa (L-DOPA) remains the gold standard of symptomatic therapy of PD it also causes severe long-term sideeffects in the form of involuntary movements (L-DOPA-induced dyskinesia, LID). The cellular and molecular mechanisms of LID formation and maintenance have started to be elucidated. Among the cellular adaptations occurring in the striatum, the brain region mainly affected in PD and LID patients, overactivation of dopamine D1 receptors, glutamate receptors and their downstream cell signalling play a central role. (ii) Objective and rationale In this project we propose to target two key integrators of dopaminergic and glutamatergic inputs, namely Ras-GRF1 and DARPP-32, that regulate Ras-ERK signalling pathway in experimental rodent models of LID. (iii) Experimental Plan Lentiviral vector (LV) mediated expression of either small harpin RNAs (shRNAs) specific for Ras-GRF1 and DARPP-32 or dominant negative constructs for Ras-GRF1 will be injected in the dorsal portion of striatum. The different and complementary expertise provided by the four partners in the project will allow us to investigate at the behavioural, cellular, electrophysiological, neurochemical and morphological level the potential therapeutic antidyskinetic action of this novel genetic approach. (iv) Expected results and their relevance We expect to block the Ras-ERK pathway and prevent LID development (priming) and maintenance. We hopefully will demonstrate that modulation of Ras-GRF1 and/or DARPP-32 activity represents a valid therapeutic approach for devising a still lacking effective treatment for LID

An innovative approach to treat levodopa-induced dyskinesia based on targeting striatal intracellular signalling. Ente finanziatore Fondazione S. Paolo

MORARI, Michele
2009

Abstract

(i) State of the art Parkinson’s disease (PD) is a neurodegenerative disorders characterised by progressive loss of dopamine innervation in the striatum. While Levodopa (L-DOPA) remains the gold standard of symptomatic therapy of PD it also causes severe long-term sideeffects in the form of involuntary movements (L-DOPA-induced dyskinesia, LID). The cellular and molecular mechanisms of LID formation and maintenance have started to be elucidated. Among the cellular adaptations occurring in the striatum, the brain region mainly affected in PD and LID patients, overactivation of dopamine D1 receptors, glutamate receptors and their downstream cell signalling play a central role. (ii) Objective and rationale In this project we propose to target two key integrators of dopaminergic and glutamatergic inputs, namely Ras-GRF1 and DARPP-32, that regulate Ras-ERK signalling pathway in experimental rodent models of LID. (iii) Experimental Plan Lentiviral vector (LV) mediated expression of either small harpin RNAs (shRNAs) specific for Ras-GRF1 and DARPP-32 or dominant negative constructs for Ras-GRF1 will be injected in the dorsal portion of striatum. The different and complementary expertise provided by the four partners in the project will allow us to investigate at the behavioural, cellular, electrophysiological, neurochemical and morphological level the potential therapeutic antidyskinetic action of this novel genetic approach. (iv) Expected results and their relevance We expect to block the Ras-ERK pathway and prevent LID development (priming) and maintenance. We hopefully will demonstrate that modulation of Ras-GRF1 and/or DARPP-32 activity represents a valid therapeutic approach for devising a still lacking effective treatment for LID
2009
Morari, Michele
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11392/1889516
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact